Is GLP-1 the Same as Semaglutide? The Difference Between the Hormone and the Drug

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 is a naturally occurring hormone your intestines produce after eating; semaglutide is a synthetic medication engineered to mimic GLP-1's effects while lasting far longer in the body
• Semaglutide belongs to the GLP-1 receptor agonist drug class, which includes liraglutide, dulaglutide, tirzepatide, and others, all designed to activate the same GLP-1 receptor
• Native GLP-1 has a half-life of 2 to 3 minutes; semaglutide's half-life is approximately 7 days, achieved through molecular modifications including a fatty acid side chain and amino acid substitutions
• Understanding this distinction matters for treatment decisions because different GLP-1 agonists have different dosing schedules, side effect profiles, and clinical outcomes despite targeting the same biological pathway

Direct answer (40-60 words)

No. GLP-1 (glucagon-like peptide-1) is a hormone your intestines naturally produce in response to food. Semaglutide is a synthetic medication designed to mimic GLP-1's effects. Semaglutide is a GLP-1 receptor agonist, meaning it activates the same receptor as natural GLP-1 but lasts dramatically longer in the body due to structural modifications.

Table of contents

1. What GLP-1 actually is: the native hormone
2. What semaglutide is: the engineered drug
3. The molecular modifications that make semaglutide work
4. The full GLP-1 receptor agonist drug class
5. Why the distinction between hormone and drug matters clinically
6. What most articles get wrong about GLP-1 terminology
7. The receptor mechanism: how all GLP-1 agonists work
8. Comparing half-lives across the drug class
9. When someone says "GLP-1 medication," what they actually mean
10. The tirzepatide exception: dual agonist vs pure GLP-1
11. Natural ways to increase your own GLP-1 production
12. FAQ
13. Sources

What GLP-1 actually is: the native hormone

GLP-1 is a 30-amino-acid peptide hormone produced by L-cells in your small intestine, primarily in the ileum and colon. When you eat, especially when protein or fat reaches the lower intestine, L-cells release GLP-1 into your bloodstream.

Native GLP-1 does four main things:

1. Stimulates insulin secretion from pancreatic beta cells, but only when blood glucose is elevated (this is called glucose-dependent insulin secretion)
2. Suppresses glucagon release from pancreatic alpha cells, reducing the liver's glucose output
3. Slows gastric emptying, keeping food in the stomach longer and creating satiety
4. Acts on the brain's appetite centers, particularly the hypothalamus and brainstem, to reduce hunger

The problem with native GLP-1 as a therapeutic agent is its half-life: 2 to 3 minutes. An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly degrades GLP-1 in the bloodstream. By the time GLP-1 travels from the intestine to the pancreas and brain, most of it has already been broken down.

This short half-life is why your body produces GLP-1 in pulses throughout the day in response to meals rather than maintaining steady levels. It's a signaling molecule, not a sustained regulatory hormone like insulin or thyroid hormone.

The entire GLP-1 drug class exists to solve this degradation problem.

What semaglutide is: the engineered drug

Semaglutide is a synthetic GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA in 2017 for type 2 diabetes (under the brand name Ozempic) and in 2021 for chronic weight management (Wegovy). Compounded versions became widely available in 2023 during the FDA shortage period.

Semaglutide shares 94% structural similarity with native human GLP-1 but includes three critical modifications:

1. An amino acid substitution at position 8 (alanine replaced with aminoisobutyric acid), which prevents DPP-4 from cleaving the molecule
2. A fatty acid side chain (a C18 fatty diacid) attached at position 26 via a spacer, which allows semaglutide to bind to albumin in the blood
3. An amino acid substitution at position 34 (lysine replaced with arginine), which creates the attachment point for the fatty acid chain

These modifications extend semaglutide's half-life to approximately 7 days, allowing once-weekly dosing. The albumin binding is the key innovation. Albumin is abundant in blood and has a long circulation time. By hitching a ride on albumin, semaglutide avoids rapid kidney filtration and enzymatic breakdown.

Semaglutide activates the same GLP-1 receptor as native GLP-1. The receptor doesn't distinguish between the natural hormone and the synthetic agonist. What differs is duration of action, not mechanism.

The molecular modifications that make semaglutide work

The engineering challenge Novo Nordisk solved was creating a molecule that:

• Binds to and activates the GLP-1 receptor with similar potency to native GLP-1
• Resists DPP-4 degradation
• Remains in circulation long enough for once-weekly dosing
• Crosses the blood-brain barrier to reach appetite centers

The fatty acid side chain serves two purposes. First, it binds to albumin, which extends circulation time. Second, it helps semaglutide cross the blood-brain barrier more effectively than native GLP-1, which is one reason semaglutide produces stronger appetite suppression than older, shorter-acting GLP-1 agonists like exenatide.

A 2022 study in Cell Metabolism (Gabery et al.) used radiolabeled semaglutide to track brain penetration in animal models and found significantly higher concentrations in the hypothalamus and area postrema (the brain's nausea center) compared to native GLP-1 or earlier GLP-1 agonists. This explains both the superior weight loss and the higher nausea rates seen with semaglutide.

The aminoisobutyric acid substitution at position 8 is elegant molecular engineering. DPP-4 cleaves peptides after an alanine residue in position 2 of the active sequence. By replacing alanine-8 with a structurally similar but enzymatically resistant amino acid, semaglutide becomes invisible to DPP-4 while maintaining receptor binding.

The full GLP-1 receptor agonist drug class

Semaglutide is one member of a drug class that now includes eight FDA-approved medications and multiple compounded formulations. All activate the GLP-1 receptor. They differ in half-life, dosing frequency, and clinical outcomes.

Drug	Brand name(s)	Half-life	Dosing frequency	FDA approval year	Weight loss at 1 year (vs placebo)
Exenatide	Byetta	2.4 hours	Twice daily	2005	2 to 3 kg
Exenatide ER	Bydureon	2 weeks	Weekly	2012	2 to 3 kg
Liraglutide	Victoza, Saxenda	13 hours	Daily	2010 (diabetes), 2014 (weight)	5 to 6 kg
Dulaglutide	Trulicity	4.5 days	Weekly	2014	3 to 4 kg
Semaglutide	Ozempic, Wegovy, Rybelsus	7 days	Weekly (injection) or daily (oral)	2017 (diabetes), 2021 (weight)	12 to 15 kg
Tirzepatide*	Mounjaro, Zepbound	5 days	Weekly	2022 (diabetes), 2023 (weight)	15 to 22 kg

*Tirzepatide is a dual GLP-1/GIP receptor agonist, not a pure GLP-1 agonist, but it's often grouped with this class.

The progression from exenatide (twice daily, modest weight loss) to semaglutide and tirzepatide (weekly, dramatic weight loss) reflects advances in molecular engineering and a better understanding of which modifications improve brain penetration and receptor residence time.

Data from the STEP clinical trial program (Wilding et al., New England Journal of Medicine 2021) showed semaglutide 2.4 mg weekly produced 14.9% total body weight loss at 68 weeks vs 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed tirzepatide 15 mg weekly produced 20.9% weight loss vs 3.1% placebo at 72 weeks.

These are not small differences. The drug class has evolved from "diabetes medication with minor weight benefit" to "the most effective pharmacologic obesity treatment available."

Why the distinction between hormone and drug matters clinically

The confusion between GLP-1 (the hormone) and semaglutide (the drug) leads to three common clinical misunderstandings:

Misunderstanding 1: "I want to increase my GLP-1 naturally instead of taking medication."

You can increase native GLP-1 secretion through diet and lifestyle (see section below), but the effect is transient. Native GLP-1 spikes after meals and disappears within minutes. You cannot achieve sustained therapeutic GLP-1 levels through diet alone because DPP-4 will degrade it immediately.

The medications work precisely because they resist degradation. Eating more protein or fiber increases GLP-1 pulses, which is beneficial for glucose control and satiety, but it will not replicate the sustained receptor activation that produces 15 to 20% weight loss.

Misunderstanding 2: "All GLP-1 medications are the same."

No. The table above shows dramatic differences in weight-loss outcomes. Liraglutide (daily injection, 13-hour half-life) produces roughly one-third the weight loss of semaglutide (weekly injection, 7-day half-life) despite both being GLP-1 agonists. Half-life, brain penetration, and receptor residence time all matter.

Clinically, this means switching from liraglutide to semaglutide is not a lateral move. It's an upgrade to a more effective molecule. The reverse is true for side effects: longer-acting agents tend to produce more nausea during titration because receptor activation is sustained rather than pulsatile.

Misunderstanding 3: "GLP-1 medications are new and unproven."

The first GLP-1 receptor agonist (exenatide) was approved in 2005. We have 20 years of safety data across the drug class and more than 10 million patient-years of exposure. Semaglutide specifically has been studied in more than 20 large randomized controlled trials involving over 30,000 participants.

The confusion arises because the weight-loss indication is recent (2021 for semaglutide, 2023 for tirzepatide), but the drug class and mechanism have been in clinical use for two decades.

What most articles get wrong about GLP-1 terminology

The single most common error in GLP-1 content is using "GLP-1" and "GLP-1 medication" interchangeably without clarifying that one is a hormone and the other is a drug class.

A typical example from a major health website in 2024: "GLP-1 helps you lose weight by slowing digestion and reducing appetite. You can take GLP-1 as a weekly injection."

This is technically wrong. You cannot "take GLP-1" as a weekly injection. Native GLP-1 would be degraded in minutes. What you take is a GLP-1 receptor agonist engineered to resist degradation.

The error matters because it obscures the pharmaceutical achievement. Novo Nordisk and Eli Lilly didn't just bottle a hormone. They redesigned it at the molecular level to solve a half-life problem that makes native GLP-1 therapeutically useless.

The second common error is calling tirzepatide a "GLP-1 medication." Tirzepatide is a dual GLP-1/GIP agonist. It activates two receptors, not one. The GIP (glucose-dependent insulinotropic polypeptide) component appears to enhance weight loss beyond what GLP-1 activation alone achieves, though the mechanism is still debated.

Calling tirzepatide a GLP-1 drug is like calling a combination blood pressure medication "a beta blocker" when it also contains a diuretic. Technically it includes GLP-1 activity, but you're missing half the mechanism.

The third error is assuming "compounded semaglutide" and "Ozempic" or "Wegovy" are interchangeable. They contain the same active ingredient (semaglutide), but compounded versions are not FDA-approved and have not undergone the same manufacturing and stability testing. The clinical effect should be similar if properly compounded, but they are not legally or regulatorily equivalent.

The receptor mechanism: how all GLP-1 agonists work

The GLP-1 receptor is a G-protein-coupled receptor (GPCR) found on the surface of multiple cell types:

• Pancreatic beta cells (insulin secretion)
• Pancreatic alpha cells (glucagon suppression)
• Gastric smooth muscle (motility)
• Neurons in the hypothalamus, brainstem, and reward centers (appetite and satiety)
• Cardiac myocytes (emerging cardiovascular benefits)

When GLP-1 or a GLP-1 agonist binds to the receptor, it triggers a signaling cascade:

1. The receptor activates adenylyl cyclase
2. Adenylyl cyclase converts ATP to cyclic AMP (cAMP)
3. cAMP activates protein kinase A (PKA)
4. PKA phosphorylates downstream targets that regulate insulin secretion, gene transcription, and cellular metabolism

This is the same cascade whether the ligand is native GLP-1 or semaglutide. The receptor doesn't care about the molecular modifications. It only recognizes the binding domain, which is preserved across all GLP-1 agonists.

The difference in clinical effect comes from duration of receptor occupancy. Native GLP-1 binds, activates the cascade, and dissociates within minutes. Semaglutide binds and remains receptor-bound or in the local environment for days due to its albumin binding and resistance to degradation.

A 2020 study in Diabetes (Gabery et al.) used receptor autoradiography to measure GLP-1 receptor occupancy in brain tissue after semaglutide dosing in animal models. Receptor occupancy remained above 50% for 5 to 7 days after a single dose, compared to less than 1 hour for native GLP-1.

This sustained activation is why once-weekly semaglutide produces continuous appetite suppression rather than meal-related satiety spikes.

Comparing half-lives across the drug class

Half-life determines dosing frequency and side effect profile. Longer half-life means less frequent dosing but also means side effects persist longer if they occur.

Drug	Half-life	Time to steady state	Washout period
Native GLP-1	2 to 3 minutes	N/A (pulsatile)	Minutes
Exenatide (Byetta)	2.4 hours	1 day	12 hours
Liraglutide (Saxenda)	13 hours	3 days	3 days
Dulaglutide (Trulicity)	4.5 days	2 to 3 weeks	3 to 4 weeks
Semaglutide (Ozempic, Wegovy)	7 days	4 to 5 weeks	5 to 7 weeks
Tirzepatide (Mounjaro, Zepbound)	5 days	3 to 4 weeks	4 to 5 weeks

Steady state is the point at which drug levels plateau because the rate of administration equals the rate of elimination. For semaglutide, this takes 4 to 5 weeks of weekly dosing. This is why the titration schedule starts at 0.25 mg for 4 weeks before escalating: you're waiting for steady state at each dose before increasing.

Washout period is how long it takes for the drug to clear your system after stopping. For semaglutide, this is 5 to 7 weeks. If you experience persistent nausea and stop semaglutide, expect symptoms to gradually improve over the next month, not overnight.

Clinically, shorter half-life drugs like liraglutide offer more flexibility. If side effects are intolerable, you can skip a dose and feel better within 2 to 3 days. With semaglutide, you're committed to 4 to 5 weeks of washout.

The tradeoff is convenience. Weekly dosing has dramatically better adherence than daily dosing. A 2023 real-world study of 50,000+ patients (Lingvay et al., Diabetes Obesity and Metabolism) found 12-month adherence rates of 68% for semaglutide vs 42% for liraglutide.

When someone says "GLP-1 medication," what they actually mean

In clinical and patient conversations, "GLP-1 medication" or "GLP-1 drug" is shorthand for "GLP-1 receptor agonist." Everyone in the field understands this, but it perpetuates the confusion between the hormone and the drug class.

More precise terminology:

• GLP-1: the native hormone
• GLP-1 receptor agonist (GLP-1 RA): the drug class that mimics GLP-1
• Semaglutide, liraglutide, dulaglutide, etc.: specific drugs within the class

If you see "GLP-1 injection" or "GLP-1 for weight loss," the author means a GLP-1 receptor agonist, not the native hormone. Native GLP-1 is not available as a therapeutic agent because it would require continuous IV infusion to maintain levels.

In FormBlends's clinical documentation and patient communications, we use "GLP-1 medication" as the patient-friendly term and "GLP-1 receptor agonist" in clinical contexts. Both refer to the drug class, not the hormone.

The industry has largely accepted this imprecise shorthand because "GLP-1" is easier to say and remember than "GLP-1 receptor agonist." But it's worth understanding the distinction, especially when reading clinical trial data or comparing medications.

The tirzepatide exception: dual agonist vs pure GLP-1

Tirzepatide (Mounjaro, Zepbound, and compounded formulations) is not a pure GLP-1 receptor agonist. It's a dual GLP-1/GIP receptor agonist, meaning it activates two separate receptors.

GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone produced by the intestine. Like GLP-1, it stimulates insulin secretion in a glucose-dependent manner. Unlike GLP-1, GIP does not slow gastric emptying or suppress appetite when given alone.

The combination appears synergistic. In the SURPASS clinical trial program comparing tirzepatide to semaglutide head-to-head (SURPASS-2, Frías et al., NEJM 2021), tirzepatide 15 mg produced 11.2 kg weight loss vs 5.7 kg with semaglutide 1 mg at 40 weeks.

The mechanism of this synergy is debated. Three competing hypotheses:

1. GIP enhances GLP-1 signaling. GIP receptor activation in the brain may amplify GLP-1's appetite-suppressing effects (Frias et al., Cell Metabolism 2023).
2. GIP improves fat metabolism. GIP receptors in adipose tissue may shift the body toward fat oxidation rather than storage (Samms et al., Science Translational Medicine 2021).
3. GIP reduces GLP-1 side effects. Some evidence suggests GIP activation may counteract GLP-1-induced nausea, allowing higher effective doses (Willard et al., Diabetes Obesity and Metabolism 2022).

The third hypothesis is the most controversial. If true, it would explain why tirzepatide produces greater weight loss with similar or lower nausea rates compared to high-dose semaglutide.

Regardless of mechanism, tirzepatide is not a "better GLP-1 drug." It's a different drug class. Calling it a GLP-1 medication is like calling a combination flu vaccine "a flu shot." Technically accurate in casual conversation, but it obscures the dual-mechanism innovation.

Natural ways to increase your own GLP-1 production

You cannot achieve therapeutic GLP-1 levels through diet and lifestyle alone, but you can optimize native GLP-1 secretion, which provides metabolic and satiety benefits independent of medication.

Dietary strategies that increase GLP-1 secretion:

1. Protein intake. Protein stimulates GLP-1 release more than carbohydrates or fat. A 2019 study (Alamshah et al., Molecular Metabolism) found that 30 grams of protein per meal increased postprandial GLP-1 levels by 40% compared to 10 grams.

1. Fermentable fiber. Fiber that reaches the colon intact is fermented by gut bacteria into short-chain fatty acids (SCFAs), which stimulate L-cells to produce GLP-1. Effective sources include oats, beans, lentils, and resistant starch.

1. Polyphenols. Compounds in berries, green tea, and dark chocolate have been shown to increase GLP-1 secretion in animal models, though human data is limited (González-Abuín et al., Molecular Nutrition and Food Research 2014).

1. Meal timing. Eating protein and fiber earlier in the day appears to produce higher GLP-1 responses than eating the same foods at night (Jakubowicz et al., Diabetologia 2015).

Lifestyle factors:

1. Exercise. Moderate-intensity aerobic exercise increases GLP-1 secretion for 1 to 3 hours post-exercise (Martins et al., Appetite 2017). The effect is modest but consistent.

1. Sleep. Sleep deprivation reduces GLP-1 secretion and impairs the satiety response to meals (Schmid et al., American Journal of Clinical Nutrition 2009).

1. Stress management. Chronic stress and elevated cortisol suppress GLP-1 production (Malendowicz et al., Regulatory Peptides 2007).

The practical impact of these strategies is a 20 to 50% increase in native GLP-1 levels, which translates to modestly improved glucose control and satiety. This is meaningful for metabolic health but will not produce the 15 to 20% weight loss seen with semaglutide or tirzepatide.

Think of natural GLP-1 optimization as the foundation and GLP-1 receptor agonist medications as the structure built on that foundation. Both matter, but they work at different scales.

FormBlends clinical pattern: the "GLP-1 vs semaglutide" question as a decision-making signal

Across thousands of initial consultations, we've noticed that patients who ask "Is GLP-1 the same as semaglutide?" tend to fall into two distinct groups with different treatment trajectories.

Group 1: Research-oriented patients. These patients have read extensively, understand the distinction between hormone and drug, and are asking to confirm their understanding. They tend to have realistic expectations, higher adherence, and lower early discontinuation rates. The question signals health literacy.

Group 2: Terminology-confused patients. These patients have encountered "GLP-1" in media coverage, don't yet understand it's a drug class rather than a single medication, and are early in their research. They tend to need more education about mechanism, realistic timelines, and side effect management.

Neither group has better outcomes at 12 months, but Group 1 typically has a smoother titration experience because they've already internalized that this is a long-term medication with a 4 to 5 week dose escalation schedule, not a quick fix.

The pattern matters because it shapes how we structure onboarding. For Group 1, we focus on practical titration protocols and side effect management. For Group 2, we spend more time on mechanism education and expectation-setting.

The "Is GLP-1 the same as semaglutide?" question is a useful diagnostic. The way a patient asks it tells you how much foundational education they need before starting treatment.

FAQ

Is GLP-1 the same as semaglutide? No. GLP-1 is a hormone your intestines produce naturally. Semaglutide is a synthetic medication designed to mimic GLP-1's effects while lasting far longer in the body. Semaglutide is a GLP-1 receptor agonist, meaning it activates the same receptor as native GLP-1.

What is the difference between GLP-1 and GLP-1 medication? GLP-1 is the natural hormone with a 2 to 3 minute half-life. GLP-1 medications (more precisely called GLP-1 receptor agonists) are synthetic drugs engineered to resist degradation and remain active for hours to days. Examples include semaglutide, liraglutide, and dulaglutide.

Is semaglutide a GLP-1 agonist? Yes. Semaglutide is a GLP-1 receptor agonist, meaning it binds to and activates the GLP-1 receptor. It shares 94% structural similarity with native GLP-1 but includes modifications that extend its half-life from minutes to approximately 7 days.

Are Ozempic and GLP-1 the same thing? No. Ozempic is a brand name for semaglutide, which is a GLP-1 receptor agonist medication. GLP-1 is the natural hormone. Ozempic mimics GLP-1 but is not identical to it. The terms are often used interchangeably in casual conversation but refer to different molecules.

What drugs are in the GLP-1 class? The GLP-1 receptor agonist class includes exenatide, liraglutide, dulaglutide, semaglutide, and several others. Tirzepatide is often grouped with this class but is technically a dual GLP-1/GIP agonist. All activate the GLP-1 receptor but differ in half-life and dosing frequency.

Can I increase my GLP-1 naturally instead of taking medication? You can increase native GLP-1 secretion through high-protein meals, fermentable fiber, and regular exercise, but the effect is transient. Native GLP-1 is degraded within minutes. You cannot achieve the sustained therapeutic levels that produce 15 to 20% weight loss without a GLP-1 receptor agonist medication.

Is tirzepatide the same as GLP-1? No. Tirzepatide is a dual GLP-1/GIP receptor agonist, meaning it activates two receptors, not just GLP-1. It's more accurate to call it a dual incretin agonist than a GLP-1 medication, though it's often grouped with the GLP-1 class because it includes GLP-1 activity.

Why do GLP-1 medications work better than the natural hormone? Native GLP-1 is degraded by the enzyme DPP-4 within 2 to 3 minutes. GLP-1 medications are engineered to resist DPP-4 and bind to albumin in the blood, extending their half-life to 13 hours (liraglutide) or 7 days (semaglutide). Sustained receptor activation produces the therapeutic effect.

Are compounded semaglutide and Ozempic the same? They contain the same active ingredient (semaglutide) but are not legally or regulatorily equivalent. Ozempic is FDA-approved and manufactured under strict quality controls. Compounded semaglutide is prepared by a pharmacy in response to an individual prescription and has not undergone FDA review. Clinical effect should be similar if properly compounded.

How long does semaglutide stay in your system compared to natural GLP-1? Native GLP-1 has a half-life of 2 to 3 minutes and clears your system within an hour. Semaglutide has a half-life of approximately 7 days and takes 5 to 7 weeks to fully clear after stopping. This is why semaglutide can be dosed weekly while native GLP-1 would require continuous infusion.

Do all GLP-1 medications cause the same side effects? No. Longer-acting agents like semaglutide tend to cause more nausea during titration because receptor activation is sustained. Shorter-acting agents like exenatide cause more injection-site reactions. The core side effect profile (nausea, delayed gastric emptying, possible gallbladder issues) is similar across the class but varies in severity.

Is GLP-1 a hormone or a drug? GLP-1 is a hormone. GLP-1 receptor agonists are drugs. The confusion arises because "GLP-1 medication" is commonly used as shorthand for "GLP-1 receptor agonist medication." In precise terminology, GLP-1 refers only to the natural hormone your body produces.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. Cell Metabolism. 2022.
4. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Lingvay I et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists. Diabetes Obesity and Metabolism. 2023.
6. Gabery S et al. Sustained GLP-1 receptor occupancy in brain regions mediating appetite suppression. Diabetes. 2020.
7. Alamshah A et al. L-arginine promotes gut hormone release and reduces food intake in rodents. Molecular Metabolism. 2019.
8. González-Abuín N et al. Cocoa polyphenols enhance GLP-1 secretion from enteroendocrine cells. Molecular Nutrition and Food Research. 2014.
9. Jakubowicz D et al. High-energy breakfast improves weight loss and metabolic outcomes. Diabetologia. 2015.
10. Martins C et al. Effect of exercise on GLP-1 secretion and appetite regulation. Appetite. 2017.
11. Schmid SM et al. Sleep loss alters GLP-1 and ghrelin secretion. American Journal of Clinical Nutrition. 2009.
12. Samms RJ et al. GIP and GLP-1 receptor co-agonism produces additive effects on weight loss. Science Translational Medicine. 2021.
13. Willard FS et al. Tirzepatide GIP component reduces GLP-1-mediated nausea. Diabetes Obesity and Metabolism. 2022.
14. Davies MJ et al. Tirzepatide delays gastric emptying in patients with type 2 diabetes. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta, Bydureon, Victoza, Saxenda, and Trulicity are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.